Edition:
India

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

2.30USD
20 Apr 2018
Change (% chg)

$-0.04 (-1.71%)
Prev Close
$2.34
Open
$2.33
Day's High
$2.33
Day's Low
$2.27
Volume
9,400
Avg. Vol
24,962
52-wk High
$4.83
52-wk Low
$1.29

Select another date:

Sat, Apr 7 2018

BRIEF-Cardiome Announces Amendment To Term Loan Agreement With CRG Managed Funds

* CARDIOME ANNOUNCES AMENDMENT TO TERM LOAN AGREEMENT WITH CRG-MANAGED FUNDS

BRIEF-Cardiome Pharma - William Hunter, President & CEO, Justin Renz, CFO Purchased Total Of 210,000 Common Shares Of Co On TSX And Nasdaq On March 26

* CARDIOME PHARMA - WILLIAM HUNTER, PRESIDENT & CEO, JUSTIN RENZ, CFO PURCHASED TOTAL OF 210,000 COMMON SHARES OF CO ON TSX AND NASDAQ ON MARCH 26 Source text for Eikon: Further company coverage:

BRIEF-Health Canada Accepts Cardiome's Xydalba For Review

* HEALTH CANADA ACCEPTS CARDIOME'S XYDALBA NEW DRUG SUBMISSION AND GRANTS PRIORITY REVIEW

BRIEF-Cardiome Pharma To Pay $2.5 Mln Termination Fee To Cipher If Proposed Arrangement Not Completed

* CARDIOME PHARMA-TERMINATION FEE OF $2.5 MILLION (CAD) PAYABLE BY CO TO CIPHER IN CERTAIN CIRCUMSTANCES IF PROPOSED ARRANGEMENT NOT COMPLETED - SEC FILING‍​

BRIEF-Cipher Pharmaceuticals And Cardiome Pharma Announce Strategic Transaction For Canadian Business Portfolio Of Cardiome

* CIPHER PHARMACEUTICALS AND CARDIOME PHARMA ANNOUNCE STRATEGIC TRANSACTION FOR CANADIAN BUSINESS PORTFOLIO OF CARDIOME

BRIEF-Cardiome Reports Q4 Loss Per Share $0.24

* CARDIOME REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Cardiome Announces Expanded Label For Aggrastat In China

* CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN

BRIEF-Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

* CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA

BRIEF-Cardiome Q3 loss per share $0.20

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

BRIEF-Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​

* Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​ Source text for Eikon: Further company coverage:

Select another date: